About INSYS Therapeutics

We are a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products.

We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients, through our cost-efficient commercial organization of approximately 50 sales professionals. In December 2012, Subsys was the second most prescribed branded transmucosal immediate-release fentanyl, or TIRF, product with 10.6% market share on a prescription basis according to Source Healthcare Analytics. In December 2011, we launched Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS, through our exclusive distributor, a leading generic pharmaceutical company. Our lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved. We intend to market Dronabinol Oral Solution and any other future supportive care products, if approved, through our commercial organization.

Latest Headlines

October 29, 2015
Insys Therapeutics Announces Its Naloxone Sublingual Spray Received Fast Track Designation From the FDA for the Treatment of Opioid Intoxication or Overdose

October 26, 2015
Insys Therapeutics Issues Statement on Its Use of Specialty Pharmacies

October 22, 2015
Insys Therapeutics to Report Third Quarter 2015 Results

More News »